Long-term denosumab therapy safe for patients with breast, prostate cancer

the ONA take:

No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases, according to a new study published online ahead of print in the journal Supportive Care in Cancer.

In the initial blinded phase 3 studies, patients with metastatic breast or prostate cancer received subcutaenous denosumab 120 mg every 4 weeks or intravenous zolendronic acid 4 mg every 4 weeks.

Denosumab was found to be superior in efficacy to zoledronic acid, and therefore patients could opt to participate in an open-label extension to receive long-term denosumab for up to an additional 2 years.

Researchers analyzed the data from the open-label extension to evaluate the safety results of extended denosumab therapy.

Results showed no new safety signals among patients who continued denosumab or among patients who switched from zoledronic acid to denosumab. Osteonecrosis of the jaw rates increased with increasing exposure to denosumab, while hypocalcemia rates were similar between the blinded treatment and open-label extension phases.

Genetic testing was associated with lower chemotherapy use in high-risk patients and greater use in
No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases.
Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied. Here, we describe safety results of extended denosumab therapy in patients with bone metastases from the open-label extension phase of two phase 3 trials.
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs